|By Marketwired .||
|September 4, 2014 08:23 PM EDT||
SARASOTA, FL--(Marketwired - September 04, 2014) - Caribbean International Holdings (PINKSHEETS: CIHN) through its subsidiary, Regenerative BioScience, Inc. ("RBS"), announced today that on August 27, 2014, a private investment group, J3 Financial, has acquired a controlling interest in the Company. Former CEO and former controlling shareholder, Steven Swank has resigned as of that same date; and effective as of August 28, 2014, the Company has appointed Mark Farber MD, PhD, MS as the new CEO of CIHN.
A spokesperson for J3 stated that: "We had been tracking CIHN for some time and found its business model very attractive. We feel that this is a company that is ready to emerge and being able to acquire the talents and services of someone like Dr. Farber, will help us establish a sound foundation for future growth. We feel very lucky to have him onboard."
The Company also said that it intends to identify, recruit and hire additional industry professionals within the emerging stem cell industry as it builds the infrastructure to support a solid but steady growth. It will also be adding administrative and other veteran executives in key positions.
The Company spokesperson also said that the Company feels it is important in today's market to keep its shareholders fully abreast of ongoing events and or news and it plans on keeping the market up to date in order to remain fully transparent with the Company's current and/or potential future shareholders and the market at large. In that light, management of the Company will shortly be releasing a Shareholder Update and other pertinent information as it becomes available.
Below is a brief background and bio on the new CEO of CIHN, Mark Farber, MD, PhD, MS.
Dr. Mark Farber received his undergraduate degree in Chemical Engineering from Brown University in Providence, RI in 2001, followed by a Masters in Science in Engineering from Brown University in 2003. He received his MD/PhD combined degree from SUNY Downstate Medical Center in Brooklyn, NY in 2013. His PhD project titled "Simultaneous functional diffuse optical tomography and EEG in freely moving rats" involved developing an emerging non-invasive optical imaging technology to investigate brain blood flow in anesthetized, freely foraging, and sleeping rats.
During the development of the diffuse optical tomography optical imager, Dr. Farber's research generated over $7 million in grants, including $130,000 from the competitive NIH Ruth Kirschstein National Research Service Award for MD/PhD students from the NIH/NINDS. The technology behind his PhD project for rat brain imaging was sold for over $750,000, and with the assistance of Dr. Farber his technology has been adapted for use in macaque research, clinical research, and the development of brain-machine interfaces.
Prior to completing his education in medicine and engineering, Dr. Farber spent three years working in developing stem cell bioreactors for use in research and tissue engineering. After completing his MS in Engineering, Dr. Farber briefly worked at ViaCell Inc. where he developed bioreactors to maximize stem cell yields from umbilical cord blood cultures. He then moved on to Harvard Medical School, where he worked in the Cardiovascular Pathology department and participated in research projects involving atherosclerosis, heart valve disease, embryology, and tissue engineering. During this time he initiated investigations into novel computerized methods of tissue collagen detection and quantification and developed bioreactor designs for stem cell based tissue engineered heart valves.
Dr. Farber has also worked at top immunology, cancer, and chemical engineering labs in Brown University and National Institutes of Health during his undergraduate education. He was also a lecturer in anatomy and biostatistics at SUNY Downstate. Dr. Farber has over 17 years experience in laboratory-based science and engineering research.
About The Company:
Caribbean International Holdings, Inc. is a holding company for Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI is focused on helping individuals protect and ensure their future quality of life through Adult Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. RBSI's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies from sports injuries to degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.
Adult stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with adult stem cells taken from the patient's own body. Regenerative BioScience is a revolution in healthcare using a patient's own adult stem cells.
For more information go to: http://www.regenerativebioscience.com/index.html.
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at http://www.sec.gov.
Dec. 9, 2016 02:15 AM EST Reads: 6,221
Dec. 9, 2016 02:00 AM EST Reads: 3,005
Dec. 9, 2016 01:45 AM EST Reads: 976
Dec. 9, 2016 01:45 AM EST Reads: 1,951
Dec. 9, 2016 01:15 AM EST Reads: 3,973
Dec. 9, 2016 01:15 AM EST Reads: 1,654
Dec. 9, 2016 12:45 AM EST Reads: 1,204
Dec. 9, 2016 12:45 AM EST Reads: 5,113
Dec. 9, 2016 12:30 AM EST Reads: 882
Dec. 9, 2016 12:00 AM EST Reads: 705
Dec. 9, 2016 12:00 AM EST Reads: 1,175
Dec. 8, 2016 09:45 PM EST Reads: 1,242
Dec. 8, 2016 09:15 PM EST Reads: 1,672
Dec. 8, 2016 09:15 PM EST Reads: 967
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Dec. 8, 2016 08:30 PM EST Reads: 1,895